Certara Corporation Launches Its Simcyp In Vitro (Data) Analysis Toolkit To Improve Drug Discovery And Development Study Results

This new standalone solution is designed to meet the needs of early-stage drug discovery and development researchers

PRINCETON, N.J.--(BUSINESS WIRE)--Certara®, the global biosimulation technology-enabled drug development company, today announced the launch of its Simcyp In Vitro (Data) Analysis (SIVA) Toolkit, version 1.0. The SIVA Toolkit is designed to enable the analysis of complex in vitro studies, including those with whole cells, tissue samples and solid dosage forms. It combines the latest model-based data analysis approaches to assess the metabolism, transport or dissolution/solubility of drugs with powerful optimization algorithms in a sophisticated statistical environment. This approach ensures that users do not need to have extensive modeling or statistical experience to use the toolkit.

“The SIVA Toolkit platform is designed specifically to analyze complex in vitro data, providing accurate values for parameters that can subsequently be used in in vitro-in vivo extrapolation paradigms, that are necessary to successfully predict in vivo behavior of drugs in physiologically-based pharmacokinetic models”

“Analysis of in vitro data from whole cell systems and dissolution studies is challenging and time consuming, and yet it is crucially important to have accurate data analysis and informed data interpretation early in the drug development process when key decisions need to be made,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D.

“The SIVA Toolkit platform is designed specifically to analyze complex in vitro data, providing accurate values for parameters that can subsequently be used in in vitro-in vivo extrapolation paradigms, that are necessary to successfully predict in vivo behavior of drugs in physiologically-based pharmacokinetic models,” added Dr. Muniz.

The SIVA Toolkit can also be used to provide reliable in vitro data for decision trees in regulatory guidelines, mechanistic-static or static models. It is a standalone product and can be purchased independently of Certara’s Simcyp Simulator. It will be useful for researchers analyzing experimental data in the pharmaceutical industry, universities and contract research organizations.

Further information about the SIVA Toolkit is available at http://www.simcyp.com/ProductServices/siva.

About Certara

Certara is a global biosimulation technology-enabled drug development company. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.